Project Grant K22CA288914
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $192K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
- This $729,690 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports metabolic intervention research to halt pancreatic cancer at Cedars-Sinai Medical Center in West Hollywood, California. The project will run from November 1, 2024 to October 31, 2027, investigating innovative approaches to disease prevention, diagnosis, treatment, and management of pancreatic cancer. As a prominent research institution,...
- The Cedars-Sinai Medical Center was awarded a $523,670 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop an artificial intelligence (AI) model for the early detection of pancreatic tumors using abdominal computed tomography (CT) scans. The key objectives are to: 1) Analyze CT image texture variations in different regions of the pancreas to enhance tumor detection, 2) Integrate distinctive morphological features of the pancreas,...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- This $147,486 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the role of transcription factor ATF4 in the early stages of pancreatic ductal adenocarcinoma (PDAC) development. The research aims to elucidate ATF4's regulatory functions in two critical early steps of PDAC - acinar to ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) formation. Through novel experimental approaches, the project...
- This $410,115 Project Grant was awarded by the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), to the University of California, San Diego (UC San Diego) to support research aimed at improving preclinical models of metastatic pancreatic cancer. The research project seeks to understand how the collagen-rich tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) drives metastasis and treatment resistance, and to develop a synthetic 3D high density...
- The federal Project Grant award in the amount of $159,304 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398). The award was granted to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on signaling pathways in tumoricidal macrophages in pancreatic cancer. The key objectives of the project include defining the role of deubiquitinases in regulating macrophage surface receptors that govern the recognition and phagocytosis...
- The federal Project Grant award of $268,345 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel immunotherapy for pancreatic cancer. The primary awardee, Sanford Burnham Prebys Medical Discovery Institute, will investigate the PSGL-1/VISTA axis as a potential target for boosting the anti-tumor immune response in pancreatic tumors. This 2-year project, with a start date of Mar 10, 2025 and end date of Feb 28, 2027, aims to elucidate...
- This $667,118 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The project will focus on studying the role of key lysosomal factors, including PLBD1 and LGMN, that are essential for the survival and growth of pancreatic ductal...
- This $156,276 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The funding supports research aimed at decoding therapeutic tumor antigens and understanding how dendritic cells contribute to anti-tumor T cell immunity, with a focus on pancreatic cancer. Key objectives include comparing tumor immunopeptidomes presented by cancer cells versus dendritic cells, and evaluating the impact of regulatory T cells on...
- This $151,263 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program to fund a research project titled "Understanding Paracrine Interactions Induced by Morphogens in PDAC" at The Trustees of Columbia University in the City of New York. The project aims to identify how active morphogen signaling shapes local immunosuppression in the pancreatic tumor microenvironment by studying the interactions between malignant...